InflaRx NV
NASDAQ:IFRX

Watchlist Manager
InflaRx NV Logo
InflaRx NV
NASDAQ:IFRX
Watchlist
Price: 2.5 USD 11.61% Market Closed
Market Cap: 147.2m USD
Have any thoughts about
InflaRx NV?
Write Note

InflaRx NV
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

InflaRx NV
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
InflaRx NV
NASDAQ:IFRX
Free Cash Flow
-€47.6m
CAGR 3-Years
-8%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Free Cash Flow
€4.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Free Cash Flow
-€300.7m
CAGR 3-Years
-6%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Free Cash Flow
-€12.7m
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Free Cash Flow
-€36.1m
CAGR 3-Years
N/A
CAGR 5-Years
-13%
CAGR 10-Years
9%
Formycon AG
XETRA:FYB
Free Cash Flow
-€31m
CAGR 3-Years
-86%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

InflaRx NV
Glance View

Market Cap
147.2m USD
Industry
Biotechnology

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. The company is headquartered in Jena, Thueringen and currently employs 59 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.

IFRX Intrinsic Value
1.95 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is InflaRx NV's Free Cash Flow?
Free Cash Flow
-47.6m EUR

Based on the financial report for Sep 30, 2024, InflaRx NV's Free Cash Flow amounts to -47.6m EUR.

What is InflaRx NV's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-6%

Over the last year, the Free Cash Flow growth was -47%. The average annual Free Cash Flow growth rates for InflaRx NV have been -8% over the past three years , -6% over the past five years .

Back to Top